PharmaShots | Incisive News in 3 Shots

Subscribe Now

High-Risk Neuroblastoma

$Y-mAbs Reports the Submission of Naxitamab's BLA to the US FDA for Relapsed/Refractory High-Risk Neuroblastoma$

Y-mAbs Reports the Submission of Naxitamab's BLA to the US FDA for Relapsed/Refractory High-Risk Neuroblastoma

April 2, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us